Relief Therapeutics Holding has the GF Score of 20, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Relief Therapeutics Holding
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Relief Therapeutics Holding GF Score Related Terms
XSWX:RLF vs KTTA, OSRH, LIMN: GF Score Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's GF Score distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's GF Score falls into.
Relief Therapeutics Holding (XSWX:RLF) has a GF Score of 20 as of Jun. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Relief Therapeutics Holding and its competitors. This is 18% above median its historical median of 17.00. Over the past decade, Relief Therapeutics Holding's GF Score has ranged from 6.00 to 46.00.
Is Relief Therapeutics Holding's GF Score too high?
Relief Therapeutics Holding's current GF Score of 20 is 18% above median its 10-year median of 17.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 46.00. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's GF Score compare to KTTA and OSRH?
Relief Therapeutics Holding's GF Score of 20 can be compared against companies in the Biotechnology industry. Historically, Relief Therapeutics Holding's own GF Score has ranged from 6.00 to 46.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current GF Score is 20, which is 18% above median its own 10-year median of 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current GF Score of 20. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current GF Score is 20, which is 18% above median its 10-year median of 17.00. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current GF Score is 20 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
GF Score: 20 (18% above median its 10-year median of 17.00)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 